High-Level Overview
11.2 Capital is an early-stage venture capital firm headquartered in San Francisco that focuses exclusively on deep-tech breakthroughs across multiple emerging technology domains[1][6]. The firm's name references Earth's escape velocity (11.2 km/s), symbolizing its mission to help founders "escape" conventional thinking and solve the world's most pressing challenges[1][6].
The firm invests in breakthrough technology companies across three primary sectors: enterprise software (including security and big data), smart hardware (AR, VR, robotics), and health (data-driven therapeutics, diagnostics, and digital health tools)[1]. 11.2 Capital operates with a clear thesis: backing technical founders at the earliest stages—from pre-seed through Series B and beyond—who are tackling transformative problems in artificial intelligence, cybersecurity, quantum computing, computational therapeutics, and synthetic biology[6]. The firm typically deploys check sizes ranging from $500K to $3M, positioning itself as a meaningful early-stage partner rather than a token investor[6].
Origin Story
11.2 Capital was established in 2014 and has evolved into a focused deep-tech investor over the past decade[2]. The fund was formed by Shelley Zhuang, who shaped the firm's investment philosophy around technical rigor and breakthrough innovation[2]. The firm's most significant institutional milestone came in November 2021 with the launch of the 11.2 Capital Deep Tech Fund, a dedicated vehicle with $101M in assets under management focused on pre-seed and seed-stage investments across biotechnology, healthcare services, SaaS, software, AI, and machine learning[1].
The firm's activity has been consistent, typically participating in 2-6 investment rounds annually, with particularly strong momentum during 2015 and 2016[2]. This steady cadence reflects a disciplined approach to deal sourcing and portfolio construction rather than boom-and-bust cycles that characterize some venture firms.
Core Differentiators
Technical Founder Alignment
11.2 Capital explicitly targets technical founders solving complex, science-based problems. The firm's portfolio includes companies like Cruise Automation (autonomous vehicles), Ginkgo BioWorks (synthetic biology), and Lucira Health (point-of-care diagnostics)—all representing deep technical challenges requiring specialized expertise[2]. This focus attracts founders who prioritize investor sophistication over brand recognition.
Sector Specialization
Unlike generalist venture firms, 11.2 Capital maintains narrow, defensible expertise across three interconnected domains: AI/cybersecurity, hardware/robotics, and biotech/health. This specialization allows the firm to provide meaningful operational support beyond capital, particularly valuable for pre-seed and seed-stage companies that need more than just funding[1][6].
Syndication Network
The firm operates within a strong ecosystem of complementary investors. 11.2 Capital frequently co-invests with Y Combinator, Felicis Ventures, and Creative Destruction Lab at early stages, and benefits from follow-on participation from Khosla Ventures and Data Collective DCVC in later rounds[2]. This network positioning ensures portfolio companies have access to downstream capital and strategic relationships.
Typical Deal Profile
The firm gravitates toward startups aged 2-3 years at investment time, with typical deal sizes in the $10-50M range[2]. This sweet spot—companies with some traction but still pre-Series C—allows 11.2 Capital to capture meaningful equity while providing hands-on support during critical scaling phases.
Role in the Broader Tech Landscape
11.2 Capital operates at the intersection of two major venture trends: the shift toward deep-tech and hard-tech investing, and the increasing sophistication of pre-seed/seed-stage capital. As traditional venture capital has consolidated around later-stage mega-rounds, early-stage specialists like 11.2 Capital have filled a critical gap for founders pursuing multi-year R&D cycles before achieving product-market fit.
The firm's focus on AI, quantum computing, and synthetic biology positions it at the forefront of technological paradigm shifts. These aren't incremental software improvements—they represent fundamental breakthroughs that could reshape industries. By backing founders in these domains at the earliest stages, 11.2 Capital influences which technical visions get funded and, consequently, which technological futures get built.
The firm's emphasis on "solving the biggest challenges facing our world" reflects a broader venture ecosystem shift toward impact-aligned investing[4]. Climate tech, computational therapeutics, and cybersecurity are no longer niche categories—they're central to venture strategy. 11.2 Capital's early positioning in these sectors has given it credibility and deal flow advantages as institutional capital increasingly flows toward deep-tech solutions.
Quick Take & Future Outlook
11.2 Capital has established itself as a credible, specialized early-stage investor in an increasingly crowded venture landscape. The firm's $101M Deep Tech Fund and consistent deal activity suggest institutional confidence in its model. However, the venture market's cyclicality will test the firm's thesis—deep-tech companies require patient capital and longer time horizons, which can be challenging during downturns when LPs demand faster returns.
Looking ahead, 11.2 Capital's influence will likely grow as AI, quantum, and biotech mature from hype cycles into infrastructure layers. The firms that backed the best technical founders at the earliest stages will capture outsized returns and influence. 11.2 Capital's positioning suggests it understands this dynamic and is building a portfolio accordingly.
The key question for the next 3-5 years: can the firm scale its operational support and network effects without losing the technical rigor and founder intimacy that define early-stage venture? Firms that maintain this balance while expanding AUM typically become the next generation of mega-funds. 11.2 Capital has the thesis, the network, and the track record to be a contender.
